Blood test co RapiDx wins FDA registration

RapiDx is a portfolio company of TechnoPlus Ventures Ltd.

Blood test developer RapiDx has received authorization of successful registration of its Rapid Ring device with the US Food and Drug Administration (FDA). RapiDx is a portfolio company of TechnoPlus Ventures Ltd. (TASE:TNPV).

TechnoPlus owns 5.73% of issued share capital of RapiDx, and 11.32% on a fully diluted basis.

The FDA registration allows RapiDx to sell Rapid Ring in the US.

Rapid Ring fits around the finger and allows quick and effective drawing of blood without need of a medical professional. The company says it reduces the pain of the lancet, and is intended for single use.

Rapid Ring can be integrated with various existing blood drawing systems, and can be an effective solution to the problem of drawing enough blood from the patient's finger.

TechnoPlus said that RapiDx intends to turn to strategic organizations in the US diagnostics market for the distribution and sale of Rapid Ring, and to continue to develop other products.

Published by Globes [online], Israel business news - - on November 25, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017